BRISTOL-MYERS SQUIBB COMPANY Interest Expense Nonoperating
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Interest Expense Nonoperating of $407.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY interest expense nonoperating for the quarter ending 2026-06-30 was $407.00M, a 16.08% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY interest expense nonoperating for the quarter ending 2026-03-31 was $411.00M, a 16.80% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY interest expense nonoperating for the quarter ending 2025-12-31 was $432.00M, a 12.90% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY interest expense nonoperating for the quarter ending 2025-09-30 was $480.00M, a 4.95% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY interest expense nonoperating for fiscal 2025 was $1.89B, a 2.88% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY interest expense nonoperating for fiscal 2024 was $1.95B, a 66.98% increase from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY interest expense nonoperating for fiscal 2023 was $1.17B, a 5.36% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY interest expense nonoperating for fiscal 2022 was $1.23B.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $407.00M 10-Q · filed 2026-07-30 | $818.00M 10-Q · filed 2026-07-30 | $1.25B derived: sum of 3 quarters · filed 2026-07-30 | $1.73B derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $411.00M 10-Q · filed 2026-04-30 | $843.00M derived: sum of 2 quarters · filed 2026-04-30 | $1.32B derived: sum of 3 quarters · filed 2026-04-30 | $1.81B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $432.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $912.00M derived: sum of 2 quarters · filed 2026-02-11 | $1.40B derived: sum of 3 quarters · filed 2026-07-30 | $1.89B 10-K · filed 2026-02-11 |
| 2025-09-30 | $480.00M 10-Q · filed 2025-10-30 | $965.00M derived: sum of 2 quarters · filed 2026-07-30 | $1.46B 10-Q · filed 2025-10-30 | $1.96B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $485.00M 10-Q · filed 2026-07-30 | $979.00M 10-Q · filed 2026-07-30 | $1.48B derived: sum of 3 quarters · filed 2026-07-30 | $1.98B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $494.00M 10-Q · filed 2026-04-30 | $990.00M derived: sum of 2 quarters · filed 2026-04-30 | $1.50B derived: sum of 3 quarters · filed 2026-04-30 | $2.02B derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $496.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.00B derived: sum of 2 quarters · filed 2026-02-11 | $1.52B derived: sum of 3 quarters · filed 2026-02-11 | $1.95B 10-K · filed 2026-02-11 |
| 2024-09-30 | $505.00M 10-Q · filed 2025-10-30 | $1.03B derived: sum of 2 quarters · filed 2025-10-30 | $1.45B 10-Q · filed 2025-10-30 | $1.77B derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $521.00M 10-Q · filed 2025-07-31 | $946.00M 10-Q · filed 2025-07-31 | $1.26B derived: sum of 3 quarters · filed 2026-02-11 | $1.54B derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $425.00M 10-Q · filed 2025-04-24 | $741.00M derived: sum of 2 quarters · filed 2026-02-11 | $1.02B derived: sum of 3 quarters · filed 2026-02-11 | $1.30B derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $316.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $596.00M derived: sum of 2 quarters · filed 2026-02-11 | $878.00M derived: sum of 3 quarters · filed 2026-02-11 | $1.17B 10-K · filed 2026-02-11 |
| 2023-09-30 | $280.00M 10-Q · filed 2024-10-31 | $562.00M derived: sum of 2 quarters · filed 2024-10-31 | $850.00M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $282.00M 10-Q · filed 2024-07-26 | $570.00M 10-Q · filed 2024-07-26 | ||
| 2022-12-31 | $1.23B 10-K · filed 2025-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |